European Union - English - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist.sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Malta - English - Medicines Authority

merck healthcare kgaa frankfurter strasse 250, 64293 darmstadt, germany - sitagliptin, metformin hydrochloride - film-coated tablet - metformin hydrochloride 850 mg sitagliptin 50 mg - drugs used in diabetes

Canada - English - Health Canada

apotex inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 50mg; 500mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 500mg

Canada - English - Health Canada

apotex inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 50mg; 1000mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 1000mg

Canada - English - Health Canada

apotex inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 100mg; 1000mg - sitagliptin (sitagliptin phosphate monohydrate) 100mg; metformin hydrochloride 1000mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.69 mg (equivalent: sitagliptin, qty 50 mg); metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; triethyl citrate; hyprolose; povidone; hypromellose; purified talc; titanium dioxide; microcrystalline cellulose; sodium lauryl sulfate; sodium stearylfumarate; iron oxide red - sitagliptin/metformin sandoz is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

Canada - English - Health Canada

apotex inc - metformin hydrochloride; sitagliptin (sitagliptin phosphate monohydrate) - tablet - 500mg; 50mg - metformin hydrochloride 500mg; sitagliptin (sitagliptin phosphate monohydrate) 50mg

Canada - English - Health Canada

apotex inc - metformin hydrochloride; sitagliptin (sitagliptin phosphate monohydrate) - tablet - 850mg; 50mg - metformin hydrochloride 850mg; sitagliptin (sitagliptin phosphate monohydrate) 50mg

Canada - English - Health Canada

apotex inc - metformin hydrochloride; sitagliptin (sitagliptin phosphate monohydrate) - tablet - 1000mg; 50mg - metformin hydrochloride 1000mg; sitagliptin (sitagliptin phosphate monohydrate) 50mg

European Union - English - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist.sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.